Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution.
about
Novel in vitro and mathematical models for the prediction of chemical toxicityPredicting volume of distribution with decision tree-based regression methods using predicted tissue:plasma partition coefficientsPhysiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationThe Simcyp population-based ADME simulatorA mechanistic, model-based approach to safety assessment in clinical developmentModeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro dataTo scale or not to scale: the principles of dose extrapolationAccelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies.Towards a rational design of solid drug nanoparticles with optimised pharmacological properties.Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitorsCombining in vitro embryotoxicity data with physiologically based kinetic (PBK) modelling to define in vivo dose-response curves for developmental toxicity of phenol in rat and human.Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework.Physiology-based IVIVE predictions of tramadol from in vitro metabolism data.Development of In Vitro-In Vivo Correlation/Relationship Modeling Approaches for Immediate Release Formulations Using Compartmental Dynamic Dissolution Data from "Golem": A Novel Apparatus.Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability.Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data.Drug-membrane interactions studied in phospholipid monolayers adsorbed on nonporous alkylated microspheres.Integrating in vitro data and physiologically based kinetic (PBK) modelling to assess the in vivo potential developmental toxicity of a series of phenols.From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools.Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients.Interaction Between Domperidone and Ketoconazole: Toward Prediction of Consequent QTc Prolongation Using Purely In Vitro Information.Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010.Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats.Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz.Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling.Prediction of the volume of distribution of a drug: which tissue-plasma partition coefficients are needed?The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development.Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.Integration of Physiologically-Based Pharmacokinetic Modeling into Early Clinical Development: An Investigation of the Pharmacokinetic NonlinearityQuantitative Systems Pharmacology Approaches Applied to Microphysiological Systems (MPS): Data Interpretation and Multi-MPS Integration.Are Physiologically Based Pharmacokinetic Models Reporting the Right C(max)? Central Venous Versus Peripheral Sampling Site.Which in vitro screens guide the prediction of oral absorption and volume of distribution?Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model.Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.Prediction of human pharmacokinetics--evaluation of methods for prediction of volume of distribution.On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development.Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.Quinolone Amides as Antitrypanosomal Lead Compounds with In Vivo Activity.Modeling kinetics of subcellular disposition of chemicals.
P2860
Q26851492-03C03A2C-C08E-4371-AC49-F862371F1B49Q27902282-3170527B-FAB6-43B8-9A44-D4AB40D8954DQ28088352-9FCFDB8F-658C-4F13-9739-386B9197A214Q28308225-A5D8055F-542C-4D6C-A812-52B164221356Q28395802-33D8F5B1-AB1D-4360-A2EF-F9C0DB3556BCQ28533793-8302CE09-5FBD-46D5-94C8-2FB28B3EA161Q28751735-BE807EAE-DDD4-4143-AD5F-4CFC3B16E85AQ28821119-4870798E-1021-44E1-B61F-3E885D96A9E4Q30372133-02350329-A40F-4AF6-8F5F-C27DF5931604Q30575798-73D349D3-DCF4-49AE-B1D9-1DA22148D7C7Q30661362-394A9BF6-FE1C-4500-9811-2A88343C677CQ30662351-5EA0537C-5A11-40BC-9ED2-3AAB1D5BF2EAQ30837825-EE8B605A-7B0C-479F-939F-05E7FDC4DC19Q30977297-EFF13BA6-C591-4E9F-AA3A-2432F87E0530Q31044030-63093D77-C52C-49B9-BC99-F2A25767F783Q31054926-BABE9DC6-6B28-48B2-9A77-B41D9C6878BDQ31091783-A15A2E3E-0B1E-4358-841C-09100931F618Q31141026-12A04E77-1332-418B-9AAA-DB636DA61CB0Q33254667-98DEF84B-E701-41D7-9A70-6A9E00DF3AFCQ33571451-C3A7C922-F56A-470C-BB42-7F721FAA9410Q34099766-E778DFEA-529C-4100-839F-93EEC37C7088Q34116212-9A14A44C-9E39-4C08-A819-0ED75E29B1D2Q34181630-5B0B7BA9-4A28-4EB6-98B0-C48E18530CAEQ34272814-1EAC3DE5-6982-467B-AA1E-B80E6CF07828Q34503553-02752595-71D8-4D55-B92D-E8BF1BA21B73Q34571360-CF535CB9-648E-4106-AC5F-B01E691A1D7AQ34924468-27EC315C-4C9F-4ACD-AFA6-D2CBD2338D12Q35560052-DBAADD10-3759-4D39-9569-BFE0EFD96638Q35668556-99ACFB87-A067-4166-B493-AFCA92EDC16EQ35676044-AECF28A0-A06D-4D68-9203-4483BD745F50Q35831603-24524024-6F58-4094-A3DB-E9C3311B232EQ35967891-A957E9D5-71B4-4D29-9F68-3114705D10C1Q36055558-8E0BD9F8-1B58-4AA6-8149-F05D93B21056Q36751935-23C43E81-9F09-4E65-9353-AC694EEC67FBQ36910606-1D920A63-4FC9-45BD-99A1-FBC3B3B92587Q36947315-07782C40-BBAE-442F-87A9-F2AE57ADE4C3Q36985094-11EDFB61-4A82-4DCA-8E0E-23F58940081DQ37008900-9C505BF6-F91D-4663-8685-4082807B1BD4Q37120204-F2B08F8A-FAAB-466F-B3D9-EF630CFCD7D3Q37194304-C11BF69E-8245-4809-A1DF-EEF6909CE6C2
P2860
Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Prediction of pharmacokinetics ...... ion of volume of distribution.
@en
Prediction of pharmacokinetics ...... ion of volume of distribution.
@nl
type
label
Prediction of pharmacokinetics ...... ion of volume of distribution.
@en
Prediction of pharmacokinetics ...... ion of volume of distribution.
@nl
prefLabel
Prediction of pharmacokinetics ...... ion of volume of distribution.
@en
Prediction of pharmacokinetics ...... ion of volume of distribution.
@nl
P356
P1476
Prediction of pharmacokinetics ...... ion of volume of distribution.
@en
P2093
Frank-Peter Theil
Patrick Poulin
P304
P356
10.1002/JPS.10005
P407
P577
2002-01-01T00:00:00Z